Introduction
Burkitt lymphoma (BL) is the most frequent childhood cancer in sub-Saharan Africa (SSA) and accounts for 50% of pediatric cancer in Malawi. 1 Although it is highly curable in resource-rich settings with intensive chemotherapy, outcomes are much worse in SSA. 2 Epstein-Barr virus (EBV) is causally associated with the endemic form of the disease seen most commonly throughout the region, in which >90% of tumor specimens are positive for EBV. 3, 4 Additionally, EBV can be detected in peripheral blood in endemic BL. Studies from Tanzania, Uganda, and Kenya demonstrated elevated EBV loads in whole blood among children with BL, [5] [6] [7] and a Brazil study demonstrated plasma EBV load declines were associated with chemotherapy response. 8 In contrast, a study of Kenyan children with endemic BL found no association between EBV load in whole blood at presentation and survival. 9 For other tumor types causally associated with EBV, plasma or whole blood EBV DNA has also shown potential utility as a biomarker, including classical Hodgkin lymphoma (cHL), 10 HIV-associated non-Hodgkin lymphoma (NHL), 11, 12 natural killer/T-cell lymphoma 13 and nasopharyngeal carcinoma. 14, 15 In SSA, BL diagnosis is often based on fine needle aspiration (FNA) without immunohistochemistry (IHC) or molecular confirmation, leading to diagnostic inaccuracy. [16] [17] [18] [19] In addition to diagnostic challenges, SSA centers typically lack advanced imaging like computed tomography (CT) and fluorodeoxyglucose positron emission tomography (FDG-PET), which are routinely used for staging and risk stratification, and to assess treatment response in resource-rich settings. As a result, there exists immense unmet need for implementable point-of-care tools to improve diagnosis and treatment for children with BL in SSA, for whom balancing benefits and risks of cytotoxic chemotherapy is difficult in environments with low supportive care infrastructure and significant treatment-related toxicity.
In this context, we hypothesized that plasma EBV DNA would be an implementable and valuable clinical biomarker for BL diagnosis and treatment in SSA, and undertook a study evaluating its utility for this purpose. Our evaluation was nested within a prospective longitudinal cohort of children with BL at a national teaching hospital in Malawi receiving standardized evaluation and treatment.
Methods

Setting and population
Kamuzu Central Hospital (KCH) is located in the Malawian capital, Lilongwe, and receives cancer referrals from the northern and central regions, serving 8-9 million people. Malawi has 10% HIV prevalence, 67% ART coverage, annual gross domestic product per capita of 343 US dollars, and Human Development Index rank of 173 out of 188 countries. [20] [21] [22] The KCH Lymphoma Study is a prospective observational cohort initiated in June 2013. All patients with pathologically confirmed lymphoproliferative disorders are eligible to participate after informed consent. For these analyses, we focused on consecutively enrolled children <18 years with BL between June 1, 2013 and October 31, 2015. To evaluate the performance of plasma EBV DNA specifically for BL diagnosis, we also compared children with BL to enrolled children with cHL, the second most common pediatric lymphoma in Malawi which is also causally associated with EBV, as well as to enrolled children initially suspected to have lymphoma but pathologically confirmed to have non-lymphoproliferative disorders.
Pathologic diagnosis
All enrolled cases were confirmed using a novel weekly telepathology consultative platform involving 2-4 pathologists in Malawi and the United States who rendered a consensus opinion, after review of cytology slides or hematoxylin and eosin stained tissue sections. This model has been described in detail previously and demonstrated excellent concordance with subsequent United States review. [23] [24] [25] Manual IHC for biopsy specimens or centrifuged cell blocks was performed locally, including CD3, CD20, CD30, CD45, CD138, Ki-67, BCL2, and terminal deoxynucleotidyl transferase (TDT). Other stains including synaptophysin and AE1/AE3 were used to distinguish lymphomas from neuroendocrine or epithelial tumors respectively when morphology was uncertain. Although we sought to obtain tissue or centrifuged cell blocks whenever possible, given frequent abdominal presentations and difficulty obtaining tissue from visceral sites with no interventional radiology, along with limited pediatric surgery and anesthesia, diagnosis was often made via cytology alone as is typical in SSA. All specimens were then shipped to the United States for secondary hematopathologist review and diagnostic confirmation, using a larger panel of automated IHC stains, including CD3, CD15, CD20, CD30, and PAX5 as required.
Clinical care
A detailed description of baseline characteristics, treatment course and toxicities, follow-up, and survival for pediatric BL patients receiving care at our center has been published. 26 Briefly, children with BL were treated uniformly with prophase COP (cyclophosphamide, vincristine, prednisone) reduction, followed by six cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) administered every 21 days. Intrathecal treatment was administered with each chemotherapy cycle. Hematopoietic growth factors were not available, and supportive care and anti-infective prophylaxis were What's new? Burkitt lymphoma (BL) is the most frequent childhood cancer in sub-Saharan Africa. Although it is highly curable in resourcerich settings, outcomes are much worse in the region and point-of-care tools are needed to improve diagnosis and treatment. Epstein-Barr virus (EBV) is causally associated with the most common endemic form of the disease. This is the first study to systematically assess plasma EBV DNA for pediatric BL diagnosis, prognosis, and response assessment in sub-Saharan Africa. The results show that plasma EBV DNA may be an implementable biomarker to facilitate diagnosis and risk-stratified, response-guided therapy for this challenging population in the region.
standardized. Stage was assigned and response assessed using physical exam, chest X-ray, and abdominal ultrasound. Presence of concurrent infections such as malaria was assessed at the treatment team's discretion based on symptoms, but not systematically, and rapid point-of-care diagnostic tests and treatment for malaria were reliably available throughout the study period.
EBV assessment
EBV was assessed in tumors and serially collected plasma specimens. EBV was evaluated in tumors by EBV-encoded RNA in situ hybridization (EBER ISH) (Leica Biosystems, Wetzlar, Germany). For quantitative plasma EBV DNA, anticoagulated plasma was collected and cryopreserved at 2808C prior to cytotoxic treatment initiation, at mid-treatment (cycle 3 Day 21), at treatment completion (cycle 6 Day 21), and whenever possible at clinical relapse. All samples were shipped to the University of North Carolina at Chapel Hill where plasma EBV was measured using a real-time quantitative polymerase chain reaction (qPCR) assay performed at the University of North Carolina Vironomics Core with a linear detection range of 2.0-8.0 log 10-copies/mL. We used a primer pair targeting a conserved region of the EBV EBNA3C gene, details of which were previously described for the detection of EBV DNA and RNA. 27, 28 This assay targets position 88933-89033 of the EBVI reference genome (NC_007605) and positions 89735-89835 of the EBVII reference genome (NC_009334) to yield a small 100 bp amplicon, and is able to detect total as well as fragmented DNA. The targeted region is highly conserved across EBV isolates, and because the assay uses SYBR green as the method of detection, it can accommodate single nucleotide polymorphisms without loss of sensitivity, as we have shown for other targets using the same assay design. 29 Given our focus on evaluating clinical utility of a potentially implementable assay within the Malawi context, we did not conduct additional molecular investigations to distinguish encapsidated from non-encapsidated plasma EBV DNA.
Statistical analysis
Cohort characteristics were summarized using simple descriptive statistics. Plasma EBV DNA was analyzed using log 10 transformed values. At baseline, we compared the proportion of children with detectable viremia and median viral loads across diagnostic groups. For children with BL, we analyzed changes in the proportion of children with detectable viremia and median viral loads during and after cytotoxic treatment.
Proportions were compared using Fisher's exact test and medians using Wilcoxon rank sum, and correlations assessed using Pearson's correlation coefficient. Follow-up time was calculated from enrollment until progression or death, loss to follow-up, or administrative censoring on May 15, 2016. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier methods, and the logrank test was used to assess survival differences between groups. Cox proportional hazards were used to estimate bivariate and multivariate hazard ratios for OS and PFS. Given non-standardized criteria for response assessment for pediatric BL in SSA, and evaluation of response using relatively crude methods in Malawi where advanced imaging is not routinely available, we principally focused time-to-event analyses on OS as the clearer and more defensible clinical endpoint in our setting. Cause of death was determined by consensus review involving two study clinicians. All analyses were performed using STATA SE version 12.1 (College Station, TX).
Ethical approval
The study was conducted in accordance with the Helsinki Declaration, after approval by the Biomedical Institutional Review Board of the University of North Carolina at Chapel Hill, the Protocol Review Committee of the Lineberger Comprehensive Cancer Center, and the Malawi National Health Sciences Research Committee.
Results
Of 137 children enrolled during the study period, baseline plasma EBV DNA was assessed in 121 (88%), including 88/94 (94%) with BL, 17/18 (94%) with cHL, and 16/25 (64%) with non-lymphoma diagnoses (Table 1) . Non-lymphoma diagnoses with plasma EBV DNA assessed included children who were pathologically confirmed to have tuberculosis (n 5 4), rhabdomyosarcoma (n 5 3), Kaposi sarcoma (n 5 2), Wilm's tumor (n 5 2), other infectious/reactive lymphadenitis (n 5 2), acute myeloid leukemia (n 5 1), salivary gland tumor (n 5 1), and nonhematopoietic small round blue cell tumor (n 5 1). Among patients tested, plasma EBV DNA was detected in 76/88 (86%) Characteristics for 88 children with pathologically confirmed BL for whom baseline plasma EBV DNA was assessed are shown in Table 2 , stratified by baseline plasma EBV detection. EBER ISH was available for 18 children (20%). Plasma EBV was detected in 12/12 patients with positive EBER ISH and 2/6 patients with negative EBER ISH (p 5 0.005), with median levels when detected 6.7 in EBER ISH positive cases versus 4.6 log 10 copies/mL in EBER ISH negative children (p 5 0.14). Additionally, children with detectable baseline plasma EBV were sicker, with worse Lansky performance status and trends toward lower albumin and higher lactate dehydrogenase (LDH). Baseline plasma EBV DNA levels were positively correlated with LDH (r 5 0.22, p 5 0.040).
During chemotherapy, plasma EBV DNA declined in most pediatric BL patients ( Fig. 1 and Supporting Information Fig.) . Compared to baseline, children had less frequently detectable plasma EBV DNA at mid-treatment (86% vs. 65%, p 5 0.003) and completion (86% vs. 70%, p 5 0.033). When detected, plasma EBV DNA levels also declined during cytotoxic treatment (median 6.1 log 10 copies/mL baseline vs. 4.4 midtreatment vs. 3.4 completion), with significant differences between viremia levels at mid-treatment versus baseline, and completion versus baseline (p < 0.0001 for both comparisons). Significant differences were not observed between midtreatment and treatment completion, for either the proportion of children with detectable plasma EBV DNA or median viremia levels when detected. Although few children had assessable plasma for EBV DNA at clinical relapse, the proportion with detectable viremia was similar to mid-treatment and completion timepoints, but viremia level was higher at relapse when detected (median 5.2 log 10 copies/mL, p 5 0.068 vs. midtreatment, p 5 0.014 vs. completion). Additionally, three children had markedly elevated outlier plasma EBV DNA values at the completion timepoint as shown in Figure 1 , all of whom had BL that was clinically refractory to first-line treatment and resulted in death within 3 months of CHOP completion, without plasma EBV DNA being subsequently assessed.
As of May 15, 2016, disease and vital status were known for 80/88 (91%) children after median follow-up of 13.2 months (IQR 9.3-26.9) among those not known to have died. For children who were untraceable by cellphone, four were from neighboring Mozambique and had traveled with their families to receive care in Malawi and subsequently returned home. Despite significant efforts to standardize care with dedicated pediatric oncology support, outcomes in the cohort overall with anthracycline-based treatment were suboptimal with OS 40% [95% confidence interval (CI) 29-51%] and PFS 31% (95% CI 21-41) at 12 months, and OS 28% (95% CI 18-40%) and PFS 27% (95% CI 17-38) at 24 months. Of 55 deaths in the cohort, 41 (75%) were attributed to relapsed or refractory BL on central adjudication and 14 (25%) to treatment-related complications. 3 Underweight was defined as weight-for-age z scores <22 if <5 years or body mass index (BMI) z scores <22 if 5 years. OS did not differ within the cohort based on baseline plasma EBV detection (Fig. 2) . However, among children with baseline plasma EBV detected, survival was significantly worse for patients with baseline level 6 log 10 copies/mL versus <6 log 10 copies/mL (p 5 0.0002). Additionally, after cytotoxic treatment initiation, survival was worse for children with persistent mid-treatment plasma EBV detection versus those without (p 5 0.041). Findings were similar as well in analyses using PFS as the primary outcome. During the study period, 15 confirmed episodes of clinical malaria were documented, and no differences were observed in baseline plasma EBV DNA detection or quantitative levels between children who developed malaria versus those who did not.
Risk factors for mortality by 12 months are shown in 
Discussion
To our knowledge, this is the first study from SSA to systematically assess utility of plasma EBV DNA for pediatric BL diagnosis, prognosis, and response assessment. Study strengths include serial assessment of EBV DNA at pre-specified clinical timepoints, within a prospective cohort of children receiving standardized treatment with minimal loss to follow-up. Additionally, high-quality pathologic diagnoses were rendered using a novel telepathology platform which is innovative for the region, [23] [24] [25] comparison was made to simultaneously enrolled children with cHL and non-lymphoproliferative disorders, and detailed evaluation facilitated adjustment for other key BL prognostic variables.
With respect to diagnosis, frequent EBV DNA detection (86%) distinguished children with BL from those referred for clinical suspicion of lymphoma who were pathologically confirmed to have non-lymphoproliferative disorders (12%). Moreover, EBV DNA levels if detected distinguished children with BL (median 6.1 log 10 copies/mL) from those with cHL (median 4.8 log 10 copies/mL), the second commonest pediatric lymphoma in Malawi which is also associated with EBV. Scarcity of diagnostic pathology in SSA has been amply documented, 30 and even where pathology services exist, diagnosis of BL and other lymphoproliferative disorders often relies on cytology with absent or limited IHC and absent molecular tools. [16] [17] [18] [19] As a result, studies in the region are invariably affected by small proportions of other aggressive NHL subtypes diagnosed as endemic BL, including lymphoblastic lymphoma, diffuse large B-cell lymphoma, or sporadic EBV-negative BL, which also occurs in SSA albeit less frequently than endemic BL and typically among older children. 26, 31 In Lilongwe, we have made significant efforts to increase use of biopsies or centrifuged FNA cell blocks for IHC confirmation of BL diagnosis, but frequent visceral and/ or abdominal presentations, limited interventional radiology, limited pediatric surgery, and limited pediatric anesthesia, often render cytologic diagnosis unavoidable despite these efforts. In such instances, plasma EBV DNA alone may not have sufficient utility to diagnose or exclude lymphoma and distinguish lymphoma subtypes, but could be included within composite diagnostic algorithms incorporating real-time pathologic, clinical, and laboratory data generated locally. We believe such an approach is more practical for SSA than tissue-based fluorescence in situ hybridization for MYC translocation to confirm all pediatric BL cases, and could substantially reduce current diagnostic uncertainties which remain a major issue for BL care and research throughout the region. IHC for MYC or Epstein-Barr nuclear antigen 1 (EBNA1) might also have applicability for improving local diagnostic accuracy. Indeed, with support from the National Cancer Institute Center for Global Health, we are now undertaking efforts to derive and validate a diagnostic score specifically for molecularly confirmed BL which incorporates plasma EBV DNA qPCR performed onsite in our Malawi laboratory, using a commercially available assay with our existing HIV RNA platform, 32 along with age, anatomic site, symptom duration, LDH, and telepathology review. Moreover, analyzable DNA can be recovered from FNA specimens, 33 which might also allow EBV detection directly from cytology slides.
With respect to prognosis and response assessment, we observed markedly elevated plasma EBV DNA among children with BL at baseline with subsequent declines during chemotherapy, as observed in Brazil, 8 and often increasing levels prior to clinical relapse. Among children with plasma EBV detected at baseline, outcomes were significantly worse for those with higher viremia, as well as those with persistent plasma EBV DNA at the midpoint of treatment. Additionally, baseline plasma EBV DNA was the only significant predictor of outcomes in multivariate analyses for these children, with each unit increase in log 10 copies/mL being associated with a 35% increased hazard of death by 12 months. Patients with baseline plasma EBV detected are arguably those children most likely to have truly endemic EBV-positive BL, as opposed to other aggressive NHL subtypes, given diagnostic challenges referenced above.
Our findings suggest EBV load monitoring could improve risk stratification and response assessment in SSA, particularly in light of the critical unmet need to optimize balance between treatment efficacy and toxicity for vulnerable, often malnourished children receiving chemotherapy in poor supportive care environments. Analogously, HIV RNA assessment is well established for antiretroviral therapy monitoring and early infant diagnosis in SSA, 34 and existing qPCR instruments could likely be adapted for EBV. In resource-rich settings, EBV DNA assessment has greater utility in plasma than peripheral blood mononuclear cells (PMBCs) for EBVpositive lymphoproliferative disorders. 35 In Kenyan children, the strength of association between cellular and plasma EBV DNA varies between healthy children and those with BL, which may also have implications for post-treatment monitoring during remission. 36 Moreover, assays utilizing plasma or whole blood can be successfully implemented even in resource-limited settings. 37 Despite efforts to intensify treatment at our center including anthracycline-based chemotherapy with pediatric oncology support, given historical experience with frequent relapses after less intensive regimens, outcomes were suboptimal as previously described, with the majority of deaths due to relapsed or refractory BL on central adjudication. 26 This is further supported by persistent EBV detection in 70% of children even after chemotherapy completion, suggesting that despite treatment intensification, achievable cumulative dose and dose intensity using this approach in our environment were insufficient to eradicate disease and cure children with advanced, aggressive BL. Better therapeutic strategies are therefore essential, which we are actively pursuing with regional colleagues through the National Cancer Institute Burkitt Lymphoma Trial Network, including greater incorporation of systemic methotrexate into front-line chemotherapy as has been reported by other groups to result in better outcomes. [38] [39] [40] [41] Incorporating newer non-cytotoxic agents, like the anti-CD20 monoclonal antibody rituximab, should also be an urgent priority especially in settings where a cytotoxic 'ceiling' is imposed by limited supportive care, rendering more intensive regimens from highincome countries impractical.
Apart from diagnostic and treatment challenges intrinsic to the Malawi setting, which we continue to address but which remain substantial, limitations of our study include referral bias at a national teaching hospital, assigning cause of death based on inference after centralized review, non-systematic assessment of concurrent malaria, and lack of distinction between encapsidated and non-encapsidated plasma EBV DNA. Additionally, plasma EBV DNA assessments were missing in some children at disease progression, and not performed after treatment completion in children without subsequent disease progression, making it difficult to clearly distinguish different plasma EBV DNA trajectories among groups of children defined by their chemotherapy response.
To conclude, quantitative plasma EBV DNA demonstrated potential utility for diagnosis, prognosis, and response assessment in a prospective pediatric BL cohort in Malawi receiving standardized anthracycline-based treatment. These findings require validation in larger regional studies, but suggest plasma EBV DNA may be an implementable and valuable biomarker for improving outcomes, through better diagnosis and more effectively risk-stratified and response-guided therapy for children with BL in SSA.
